Clinically reviewed by Dr. Sarah Boss, MD
Tell your prescriber about stopping, reducing or restarting smoking, particularly when taking clozapine or olanzapine. New suicidal thoughts or severe behavioral changes need prompt assessment. A seizure, collapse or serious breathing difficulty requires emergency help.
Medication can make a quit-smoking attempt more manageable by reducing cravings and nicotine withdrawal. It works best as part of a plan that also addresses routines, stress, support and follow-up. The available options are not interchangeable, and their licenses differ between countries. A useful discussion compares the actual medicines, the person’s health and previous quit attempts rather than asking which product guarantees success.
What a smoking-cessation assessment should include
Describe cigarette and other tobacco use, vaping, nicotine products, when cravings are strongest and what happened during previous attempts to stop. Include medicines, pregnancy or breastfeeding, physical illness and mental-health history. A change in smoking may affect an existing prescription even before a quit-smoking medicine is added.
Ask what kind of support is available and how the quit plan will be reviewed. The aim is a workable approach, not a test of willpower. A previous unsuccessful attempt can provide useful information about triggers, withdrawal, administration difficulties or an unsuitable product. It does not establish that medicines or counseling cannot help.
The main medication options
WHO recognizes nicotine replacement therapy, varenicline, bupropion and cytisine, also called cytisinicline, as effective tobacco-cessation options. It recommends combining medication with behavioral support. This global recommendation is not a statement that all four are approved or available in every country or suitable for every individual. [1]
For example, US CDC guidance lists nicotine replacement products, varenicline and bupropion, while the UK NICE pathway also includes cytisinicline for eligible adults. The prescriber or pharmacist should identify the local product, any age restriction and the relevant instructions. Do not copy a foreign treatment course merely because the active ingredient sounds familiar.
Nicotine replacement therapy
Nicotine replacement therapy, or NRT, supplies nicotine without burning tobacco. Patches provide a steadier background supply, while products such as gum or lozenges can address breakthrough urges more quickly. Available forms and whether they require a prescription differ by country. Each formulation has its own technique and precautions. [2]
Using a patch with a suitable shorter-acting NRT product can be more effective than using one NRT form alone. That does not mean adding several products without a plan. Ask which combination, strength and administration method fits the pattern of smoking. An incorrectly used gum or lozenge may cause discomfort or provide less benefit than expected. [3]
NRT is not equivalent in harm to smoking cigarettes: avoiding combustion removes exposure to many smoke-related toxicants. Its purpose is to make stopping tobacco more achievable, with later review of nicotine treatment as appropriate. Do not rush a useful treatment change simply to meet an arbitrary deadline for using no nicotine at all. [4]
Varenicline
Varenicline acts at nicotine-related receptors, reducing cravings and the rewarding effects of smoking. It does not contain nicotine. Treatment has a planned schedule and quit approach, so it should not be used as an occasional tablet after a difficult craving. Discuss previous experience, kidney health and other relevant conditions before starting. [5]
Nausea, sleep disturbance and vivid dreams can occur. Report persistent or troubling symptoms, and seek prompt advice for major mood or behavioral changes. A previous mental-health diagnosis does not itself answer whether the medicine is suitable; the actual clinical situation and monitoring plan matter. Do not change the amount or add another cessation medicine without review.
Bupropion for smoking cessation
Bupropion is a non-nicotine medicine used in particular sustained-release smoking-cessation products. It also has other psychiatric uses, but a smoking-cessation prescription and an antidepressant prescription should not be duplicated without checking the total treatment. Bring every brand and formulation to the medication review. [6]
Important contraindications include seizure disorder and current or past anorexia nervosa or bulimia, with additional concerns around MAO inhibitors and certain withdrawal situations. Insomnia, dry mouth, nausea and blood-pressure effects also need consideration. Bupropion is not a suitable way to manage an unsupervised alcohol or sedative detox. A seizure or severe allergic reaction requires urgent medical care.
Cytisinicline and country-specific instructions
Cytisinicline, formerly called cytisine, is another nicotine-receptor partial agonist. NICE includes it in the adult UK pathway but advises against use below eighteen or from age sixty-six onward. The actual product has additional contraindications, including pregnancy, breastfeeding and particular cardiovascular conditions. [7]
The cited UK course requires a specific quit date and changing instructions over its duration. Continued smoking or additional nicotine can worsen adverse effects. That plan is not interchangeable with research regimens or another country’s product. Authorization should be checked locally; a recommendation in international guidance is not itself regulatory approval.
How to choose without declaring a universal winner
Consider previous response, the reason an earlier attempt ended, health conditions, other medicines, preferences, cost and practical access. Someone who struggles to remember tablets may face a different challenge from someone who cannot tolerate a particular NRT formulation. A person with kidney disease or a seizure history needs a different safety assessment from a person without those conditions.
NICE identifies cytisinicline, varenicline and combined short- and long-acting NRT among effective options when paired with behavioral support. The comparative recommendation should guide discussion, not override an individual contraindication or preference. Ask which option is realistic for you and what will happen if it causes difficulties. [7]
Nicotine withdrawal and mental health
Cravings, irritability, poor concentration, sleep disturbance and appetite changes can occur after reducing nicotine. A medicine may reduce these symptoms without eliminating every urge. Some symptoms also overlap with adverse effects or an underlying mental-health condition, so a brief timeline can help the clinician interpret what has changed.
Marked depression, suicidal thoughts, severe agitation or a major behavioral change should not be dismissed as routine withdrawal. Seek prompt assessment, and use emergency services when there is immediate danger. Agree in advance how the stop-smoking service will coordinate with a mental-health clinician, especially if previous quit attempts coincided with significant deterioration.
Smoking cessation can change psychiatric drug levels
Tobacco smoke, rather than nicotine alone, can alter the metabolism of medicines such as clozapine and olanzapine. Stopping or substantially reducing smoking may therefore change drug exposure even when NRT is used. Restarting smoking can also affect treatment. The prescriber needs to know about both planned and unplanned changes.
Do not alter psychiatric doses yourself. Ask whether symptoms, blood levels or other monitoring need review, and make the plan clear before an admission to a smoke-free setting. The smoking and psychiatric medicines guide explains this separate interaction issue. A cessation medicine does not replace the need to coordinate existing care. [8]
Behavioral support and managing difficult situations
Counseling can help plan for urges, stress and familiar smoking situations. Support may be individual, group-based, telephone-based or digital. Choose a format that can be used consistently and ask how to reconnect after a lapse. Medication and behavioral support address different parts of the problem and can be used together. [2]
Think through work breaks, time with other smokers, alcohol-related cues and the first days of a changed routine. Decide what information a supporter needs and what kind of help would actually be welcome. A practical plan is more useful than a promise never to have another craving. Setbacks should trigger reassessment rather than loss of access to support.
Pregnancy, younger people and vaping
Pregnancy, breastfeeding and adolescence need specific clinical advice; the adult options described here should not simply be carried across unchanged. Product age restrictions and pregnancy contraindications differ. Discuss the risks of continued tobacco use and the suitable treatment choices with the relevant clinical team rather than abandoning a quit attempt because one medicine is unsuitable.
Vaping is also a distinct question. UK guidance discusses nicotine-containing e-cigarettes as one smoking-cessation option, but that does not make every vaping product a licensed medicine or establish its suitability for a nonsmoker. Treatment for stopping cigarettes and treatment for stopping vaping should be identified clearly, with local evidence and regulatory status checked. [7]
Continuing care and the end of medication
The end of a medicine course should include a review of tobacco use, cravings, mood, adverse effects and future support. The timing depends on the product and response. Do not assume all medicines need the same taper, or that a return of cravings requires immediately restarting an old course. Follow the agreed instructions and seek advice about a repeat attempt.
Smoking-cessation medicines do not treat withdrawal from alcohol, opioids or benzodiazepines. Someone working on several substance-related goals may need coordinated plans rather than one generic detox approach. Explain what else is being changed and who is monitoring it. Immediate safety needs should take priority without losing sight of longer-term tobacco treatment.
Frequently asked questions
Is using NRT just as harmful as smoking?
No. Medicinal nicotine avoids tobacco combustion and is substantially less harmful than continued smoking. Suitability and correct use still matter, particularly in specific medical circumstances.
Can I combine any two quit-smoking medicines?
No. Some combinations, such as a patch with appropriate shorter-acting NRT, have established roles. Other combinations require clinical review, and cytisinicline has specific precautions about additional nicotine.
Does a lapse mean treatment has failed permanently?
No. Review what happened and follow the instructions for the actual medicine. The response to a lapse is product-specific; support should continue rather than being replaced by blame.
What should I ask at the next review?
Ask about correct use, remaining cravings, side effects, interactions with psychiatric medicines and the plan after the course. The medication-review checklist can help prioritize those questions.
